Loading...
OTCM
CUBT
Market cap7mUSD
Jul 15, Last price  
0.01USD
1D
1.51%
1Q
-31.91%
Jan 2017
4,275.00%
IPO
-99.13%
Name

Curative Biotechnology Inc

Chart & Performance

D1W1MN
OTCM:CUBT chart
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
15.45%
Rev. gr., 5y
%
Revenues
0k
323,825132,324113,26411,0910000000
Net income
-6m
L+3.79%
-63,138-77,919190,836-17,400-22,983-29,914331,953-4,670,255-5,340,354-5,604,893-5,817,253
CFO
-487k
L-68.31%
-35,679-20,9920-5,891-150-150-150-190,093-1,604,035-1,535,573-486,585

Profile

Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.
IPO date
Jul 11, 2001
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
1,933
4,428
Unusual Expense (Income)
NOPBT
(1,933)
(4,428)
NOPBT Margin
Operating Taxes
1,175
Tax Rate
NOPAT
(1,933)
(5,603)
Net income
(5,817)
3.79%
(5,605)
4.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
542
268
BB yield
-3.85%
-2.35%
Debt
Debt current
2,258
1,071
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
2,202
1,012
Cash flow
Cash from operating activities
(487)
(1,536)
CAPEX
(77)
Cash from investing activities
(14)
(77)
Cash from financing activities
498
1,001
FCF
(2,397)
(2,255)
Balance
Cash
56
59
Long term investments
Excess cash
56
59
Stockholders' equity
(38,137)
(32,552)
Invested Capital
37,253
31,225
ROIC
ROCE
218.56%
333.60%
EV
Common stock shares outstanding
662,161
572,010
Price
0.02
6.50%
0.02
-62.96%
Market cap
14,104
23.28%
11,440
-57.71%
EV
16,308
12,452
EBITDA
(1,843)
(4,420)
EV/EBITDA
Interest
1,357
1,170
Interest/NOPBT